← Eichor
Study identifier: NCT06877715 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Autistic Symptomatology and Sensory Profile in Children With Prader-Willi Syndrome

Condition: Prader-Willi Syndrome  ·  Sponsor: University Hospital, Toulouse

PhaseN/A
Planned participants75
Who can joinAll sexes, 3 Years to 16 Years
Healthy volunteersNo

About this study

Prader-Willi Syndrome (PWS) is a rare neurodevelopmental disorder stemming from genetic damage in the 15q11-q13 region, leading to hypothalamic dysfunction. Individuals with PWS often exhibit social interaction challenges, intellectual deficits, significant eating disorders, mood disturbances, and sensory-related autistic features. Although PWS is recognized by DSM-5 as a genetic cause of Autism Spectrum Disorder (ASD), ASD diagnosis in PWS remains rare in France. The CASSPER study aims to investigate the distinct autistic and sensory profiles in children with PWS, also analyzing the potential impact of early oxytocin treatment on these manifestations, in line with recommendations for early and tailored intervention.

This description comes directly from the study's public registry record.

Talk to the study team

Nadege ALGANS  ·  0561777204  ·  algans.n@chu-toulouse.fr

Always discuss trial participation with your own doctor first.

Locations (1)

Children HospitalToulouse, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06877715